49 research outputs found
Polychlorinated biphenyl (PCB) half-lives in humans: A systematic review
This manuscript presents a systematic review of PCB half-lives reported in the scientific literature. The review was completed in accordance with PRISMA guidelines and included a review of almost 1000 peer-reviewed publications. In total, 26 articles were found to report half-lives in humans, with the majority of data coming from studies performed in North America on individuals suspected to have been exposed to PCBs. Terminology for reporting PCB half-lives was inconsistent, so we have attempted to consolidate this and recommend using either “apparent half-life” or “intrinsic half-life” in future studies. Within the literature, values for reported half-lives varied considerably for different PCBs. Less chlorinated PCBs generally have shorter half-lives than more chlorinated PCBs. It was interesting to note the large variability of half-lives reported for the same PCB. For example, the reported half-life for PCB 180 varied by nearly 3 orders of magnitude (0.34 years–300 years). Our review identified that the half-lives estimated were largely dependent on the studied cohort. We discuss the importance of PCB body burden, degree of chlorination and PCB structure, gender, age, breastfeeding, BMI, and smoking status on half-life estimations. We also identified significantly shorter half-lives for some PCBs in occupationally exposed individuals compared to results reported from the general population. PCB half-lives are not the same for every PCB or every individual. Therefore, careful consideration is needed when these values are used in human exposure studies
Prediction of copper and chromium concentrations in bean leaves based on an artificial neural network model
Sorption of Cd in Soils: Pedotransfer Functions for the Parameters of the Freundlich Sorption Isotherm
Head to head comparison of widely used HIV-1 drug resistance algorithms: Retrogram ® and VGI-Trugene HIV-1 ®
Clinical evaluation of rule based and phenotype driver HIV-1 genotype interpretation systems: evidence from the GenPherex Study
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype:Concordance analysis and correlation with clinical outcome in heavily treated patients
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype:Concordance analysis and correlation with clinical outcome in heavily treated patients
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: Concordance analysis and correlation with clinical outcome in heavily treated patients
We compared 2 rules-based genotype interpretation systems and real or virtual phenotype through a retrospective analysis of a prospective trial. Genotypes were determined with VircoGEN II (VIRCO) and were interpreted with either RetroGram 1.4 or TRUGENE HIV-1 ( guidelines 3.0) or original virtual phenotype ( Virtual Phenotype; VIRCO), as available in the year 2000. Among 188 human immunodeficiency virus (HIV) type 1 isolates, overall concordance (kappa agreement) was observed for the 2 rules-based systems, whereas striking discordances were noted between them and real and virtual phenotype interpretations for stavudine, didanosine, zalcitabine, abacavir, and amprenavir (kapp